New cancer clinical trial: A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer (Affibody-3).

Published on: August 31, 2018 at 12:00PM
Condition:   HER2-positive Breast Cancer
Intervention:   Diagnostic Test: ABY-PET
Sponsors:   Henrik Lindman;   Roche Pharma AG;   Swedish Cancer Society;   Affibody;   Swedish Breast Cancer Group
Recruiting
https://ift.tt/2PnIjbW